PharmaBlock Sciences Nanjing Inc Class A (300725) — Cash Flow-to-Debt Ratio
PharmaBlock Sciences Nanjing Inc Class A (300725) has a Cash Flow-to-Debt Ratio of 0.13x as of September 2025, meaning its operating cash flow of CN¥83.36 Million could theoretically repay 0% of its total liabilities (CN¥645.64 Million) in one year. See free cash flow generation of PharmaBlock Sciences Nanjing Inc Class A to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
PharmaBlock Sciences Nanjing Inc Class A Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for PharmaBlock Sciences Nanjing Inc Class A across 12 annual periods. Also explore net asset momentum of PharmaBlock Sciences Nanjing Inc Class A to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for PharmaBlock Sciences Nanjing Inc Class A (2013–2024)
Year-by-year debt coverage analysis for PharmaBlock Sciences Nanjing Inc Class A. For market capitalisation and broader financial context, see market cap of PharmaBlock Sciences Nanjing Inc Class A.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.16x | CN¥302.82 Million | CN¥1.95 Billion | ▲ +43.1% |
| 2023 | 0.11x | CN¥246.84 Million | CN¥2.27 Billion | ▼ -2.9% |
| 2022 | 0.11x | CN¥246.61 Million | CN¥2.20 Billion | ▼ -58.7% |
| 2021 | 0.27x | CN¥238.03 Million | CN¥879.21 Million | ▼ -47.1% |
| 2020 | 0.51x | CN¥271.51 Million | CN¥530.57 Million | ▲ +16.1% |
| 2019 | 0.44x | CN¥127.04 Million | CN¥288.27 Million | ▼ -55.6% |
| 2018 | 0.99x | CN¥160.16 Million | CN¥161.43 Million | ▲ +15.8% |
| 2017 | 0.86x | CN¥54.64 Million | CN¥63.80 Million | ▲ +69.3% |
| 2016 | 0.51x | CN¥22.76 Million | CN¥45.00 Million | ▼ -52.4% |
| 2015 | 1.06x | CN¥27.52 Million | CN¥25.92 Million | ▲ +28.2% |
| 2014 | 0.83x | CN¥11.91 Million | CN¥14.38 Million | ▼ -32.3% |
| 2013 | 1.22x | CN¥18.32 Million | CN¥14.97 Million | — |